Oncoinvent presents first half 2026 results
Oslo, Norway, 27 August 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its first half 2026 results. Presentation: Oncoinvent’s management will give an online presentation to investors, analysts and the press at 10:00am CEST today. It will be possible to submit questions during the presentation. · Presenters: CEO Oystein Soug, CFO Ramzi Amri · Time: 10:00am CEST · Webcast link: https://qcnl.tv/p/
Read releases like this the second they cross the wire.
1,400+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 72-hour free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →